[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100365984":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":25,"responsibleParty":41,"collaborators":43,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Sample collection","Plasma and BAL sample collection",[13],{"name":14,"affiliation":15,"role":16},"Isabel Spriet, PharmD, PhD","UZ Leuven","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+32 16 34 30 80","isabel.spriet@uzleuven.be",{"name":23,"role":19,"phone":20,"phoneExt":7,"email":24},"Ruth Van Daele, PharmD","ruth.vandaele@uzleuven.be",[26],{"facility":15,"status":27,"city":28,"state":7,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Leuven","3000","Belgium","BE",{"type":33,"coordinates":34},"Point",[35,36],4.70093,50.87959,{"lat":36,"lon":35},[39,40],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},{"name":23,"role":19,"phone":20,"phoneExt":7,"email":24},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[44],{"name":45,"class":6},"KU Leuven","100365984","impact-of-capillary-leak-and-hypoalbuminemia-on-pkpd-of-anidulafungin-and-caspofungin-in-critically-ill-patients-100365984",false,"NCT04045366","Impact of Capillary Leak and Hypoalbuminemia on PK\u002FPD of Anidulafungin and Caspofungin in Critically Ill Patients","Inclusion Criteria:\n\n* Treatment with anidulafungin or caspofungin\n* Admitted to an ICU ward\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* DNR 2 or 3","ALL","18 Years",{"count":55,"type":56},60,"ESTIMATED","OBSERVATIONAL","This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the echinocandins (caspofungin or anidulafungin) in critically ill patients.",[60],"Critically Ill Patients",[62,63,64],"Pharmacokinetics","Echinocandins","Critically ill patients","2024-07-02",{"date":67,"type":68},"2024-07-03","ACTUAL",{"date":70,"type":68},"2012-09-21",{"date":72,"type":56},"2025-12-31",{"name":5,"class":6},1]